Discovery. Development. Manufacturing.
One Trusted CRDMO Partner
Usually: Six weeks after the show you are still waiting on a feasibility view, and the programme has not moved.
With Aurigene: Accelerated IND-enabling timelines of 6-12 months for complex small molecules and 9 months for biologics.
Usually: Drug substance and drug product sit with different suppliers - managing the seam between them becomes your job, not theirs.
With Aurigene: One integrated global partner from discovery to commercial manufacturing, across 16 USFDA sites, eliminating handoff risks.
Usually: Each supplier runs its own QMS - reconciling them and scheduling audits is your overhead, not theirs.
With Aurigene: Our Quality-First approach ensures patient safety and data integrity remain uncompromised.
Usually: Most CDMOs top out at gram scale for complex peptides - commercial volume means switching supplier and revalidating.
With Aurigene: Peptides & Fragments synthesized via SPPS/ LPPS/ TAPS from milligram to commercial tonnage.
Usually: Capacity is "available" right up until you ask for a firm date against your timeline.
With Aurigene: 4,100 m³ across 1, 250 reactors; 2,100 MT API per year; 20 KL biologics DS across sites from India, UK and Mexico.
Route scouting and process development through GMP API and commercial supply, including potent and high-containment work.
Solid-phase and solution-phase peptide synthesis, scaled to commercial volumes - capacity most mid-tier CDMOs cannot offer.
Antibody discovery, cell line development, upstream and downstream processing, GMP drug substance and fill finish across four modalities.
Discovery chemistry and biology at one end, GLP toxicology, CMC regulatory and lifecycle support at the other - the parts most CDMOs make you source separately.
CPHI Milan, 06-08 October 2026.